:
Innovative gene‑editing and gene‑addition therapies (e.g., Casgevy, Lyfgenia, lovo‑cel, exa‑cel) are now FDA‑approved and are being rolled out in specialized centers, offering potential cures for many patients with severe SCD.
:
New in‑clinical and emerging therapies include CRISPR‑based exa‑cel and reni‑cel, P‑selectin inhibitors such as inclacumab, fetal‑hemoglobin modulators like mitapivat, and IL‑1β blockers such as canakinumab, all aimed at reducing pain crises and organ damage.
: Despite this progress, major hurdles remain:
high costs, complex conditioning regimens, limited infrastructure, and uneven access—especially in low‑ and middle‑income countries where SCD burden is highest.
Sources:
FDA Approves First Gene Therapies to Treat Patients with Sickle ...
In the News: Groundbreaking gene therapy for sickle cell disease
Research Reveals Avenues for Informing and Improving Sickle Cell ...
New UCLA graduate is among first to receive leading-edge sickle ...
Sickle Cell Disease Competitive landscape | Companies, Therapies
Creating the World's First CRISPR Medicine, for Sickle Cell Disease
Gene Editing Therapy Shows Success Against Severe Sickle Cell ...
New Wave of Potentially Curative Treatment Offers Hope for Sickle ...
New Directions for Sickle Cell Therapy in the Genome Era - Working ...
Sickle cell anemia: What's new and what's next | Penn Medicine
Current and Future Therapeutics for Treating Patients with Sickle Cell Disease - PubMed
Scientific Advances in Sickle Cell Disease
Born at UC Berkeley: a breakthrough in the treatment of sickle cell ...